MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ARVN - Arvinas Inc
$76.14
1.87(2.52%)9:00:00 PM 2/24/2021
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/18/2021ARVN
    What Kind Of Shareholders Hold The Majority In Arvinas, Inc.'s (NASDAQ:ARVN) Shares?

    Every investor in Arvinas, Inc. ( NASDAQ:ARVN ) should be aware of the most powerful shareholder groups. Large...

    02/8/2021ARVN
    Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day

    NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on Thursday, February 11 at 4:30 p.m. ET. A live audio webcast of the presentation will be ...

    12/28/2020ARVN
    Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares

    NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced that the underwriters of its previously announced underwritten public offering of common stock, which closed on December 18, 2020, have exercised in full their option to purchase additional shares of common stock at the public offering price, less underwritin...

    12/23/2020ARVN
    3 “Strong Buy” Stocks Insiders Are Snapping Up

    Insiders are an interesting lot. From an investor’s perspective, corporate officers have access to information – and information has always been the key to successful investing. Company CEOs, exec VPs, board members – these are ‘insider’ positions, officers in position to know what is happening, or likely to happen, to a company and its stock.And yes, they do trade their company’s stock. They are privy to the inner workings of their companies, and that knowledge puts them in a far better positio...

    12/16/2020ARVN
    Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More

    Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.

    12/16/2020ARVN
    Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock

    NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 per share, before underwriting discounts and commissions. In addition, Arvinas has granted the underwriters an option for a period of 30 days to purcha...

    12/16/2020ARVN
    Arvinas’ Cancer Drug Has Blockbuster Potential, Says Analyst

    Arvinas (ARVN) investors couldn’t have asked for a better start to the week. ARVN stock hit the ground running as shares surged nearly 150% over the past two trading sessions. The uptick came after the company announced positive developments for 2 of its potential cancer treatments.Interim data from the Phase 1 trial for ARV-471 in heavily pretreated patients with locally advanced or metastatic ER positive / HER2 negative breast cancer, displayed evidence of anti-tumor activity and signs of stro...